Alexandra Trkola researcher
Trkola, Alexandra 1965-
Trkola, Alexandra
VIAF ID: 179155284912987062763 (Personal)
Permalink: http://viaf.org/viaf/179155284912987062763
Preferred Forms
- 100 0 _ ‡a Alexandra Trkola ‡c researcher
-
- 100 1 _ ‡a Trkola, Alexandra ‡d 1965-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | |
CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity | |
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies | |
Co-receptors for HIV-1 entry | |
Complement dependent trapping of infectious HIV in human lymphoid tissues | |
Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection | |
Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors | |
Conformation of the native HIV-1 envelope protein raises questions for vaccine design | |
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies | |
Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. | |
Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. | |
Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry | |
Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization | |
Divergent effects of cell environment on HIV entry inhibitor activity. | |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection | |
Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors | |
Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations | |
High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children | |
High-throughput sequencing of human immunoglobulin variable regions with subtype identification. | |
The HIV-1 Entry Process: A Stoichiometric View | |
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use | |
HIV-1 replication activates CD4+ T cells with specificities for persistent herpes viruses | |
HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution | |
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy | |
HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. | |
HIV-host interactions: vital to the virus and key to its inhibition. | |
HIV: Potency needs constancy | |
HIV rebounds from latently infected cells, rather than from continuing low-level replication | |
HIV RNA in plasma rebounds within days during structured treatment interruptions | |
HIV sensitivity to neutralization is determined by target and virus producer cell properties | |
HIV type 1 coreceptors, neutralization serotypes, and vaccine development | |
HIV vaccines: an attainable goal? | |
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. | |
Humoral immunity to HIV-1: neutralization and beyond. | |
Immune senescence: relative contributions of age and cytomegalovirus infection | |
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. | |
In vivo binding and retention of CD4-specific DARPin 57.2 in macaques | |
Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study | |
Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity | |
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies | |
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization | |
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). | |
Loss of Viral Control in Early HIV‐1 Infection Is Temporally Associated with Sequential Escape from CD8+T Cell Responses and Decrease in HIV–1–Specific CD4+and CD8+T Cell Frequencies | |
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions | |
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. | |
Mathematical models: a key to understanding HIV envelope interactions? | |
Metagenomic sequencing complements routine diagnostics in identifying viral pathogens in lung transplant recipients with unknown etiology of respiratory infection | |
Metagenomic Virome Sequencing in Living Donor and Recipient Kidney Transplant Pairs Revealed JC Polyomavirus Transmission | |
MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing | |
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. | |
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus | |
Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity | |
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors | |
OMIP-047: High-Dimensional phenotypic characterization of B cells. | |
Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples | |
The orientation of HIV-1 gp120 binding to the CD4 receptor differentially modulates CD4+ T cell activation | |
Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation | |
Peptidomimetic inhibitors targeting the CCR5-binding site on the human immunodeficiency virus type-1 gp120 glycoprotein complexed to CD4. | |
Persistent mammalian orthoreovirus, coxsackievirus and adenovirus co-infection in a child with a primary immunodeficiency detected by metagenomic sequencing: a case report. | |
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. | |
Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions. | |
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140 | |
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked | |
Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. | |
Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol | |
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement | |
Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs | |
Reply to correspondence 'Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process' by Gonzalez et al., Retrovirology 2017. | |
Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. | |
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 | |
Scale-up of recombinant protein purification by hydrophobic interaction chromatography | |
Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo | |
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults | |
Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design | |
Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells | |
Therapeutic antibodies in HIV treatment--classical approaches to novel advances | |
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses | |
Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs | |
The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients | |
Unbiased metagenomic sequencing complements specific routine diagnostic methods and increases chances to detect rare viral strains. | |
Use of alternate coreceptors on primary cells by two HIV-1 isolates | |
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors | |
Wechselwirkung von Chemokinrezeptoren, Chemokinen und HIV-1 | |
Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells |